Upcoming Earnings Reports To Watch: PLAY, AVGO, LULU

While we are not in a traditionally busy stretch for earnings reports, there are still several noteworthy companies set to announce their latest results in the upcoming week. Q3 earnings have been strong across the board, so it will be interesting to see whether these reports will continue that trend and inspire strong trading for the remainder of the calendar year.

With that said, investors can always use the Zacks Earnings Calendar to plan out their schedules for earnings, dividend announcements, and other important financial releases. This handy tool is your perfect one-stop-shop to properly prepare for the market events that will have an impact on your own portfolio.

And today, we’ve made that task even easier for you. Using the Earnings Calendar, we looked ahead to next week and selected the biggest reports to watch. Make sure to keep an eye on these companies as they prepare to report during the week of December 4.

1. Dave & Buster’s Entertainment, Inc. ( (NASDAQ:PLAY) )

Dave & Buster’s is scheduled to report its latest earnings results after the market closes on December 5. Thanks to its unique arcade-eatery style restaurants, Dave & Buster’s was able to stick out in the struggling retail restaurant industry throughout 2016. But that momentum did not continue into 2017, and shares of PLAY are down about 5% on the year.

Heading into its report date, Dave & Buster’s is sporting a Zacks Rank #3 (Hold). Our latest consensus estimates are calling for earnings of $0.24 per share and revenues of $255.38 million, which would represent year-over-year growth rates of -6.00% and +11.68%.

PLAY has successfully surpassed earnings estimate in 12 consecutive quarters, but its stock has failed to respond positively recently. Rising labor costs should drag down profits, and a lack of international exposure means the company won’t benefit from an improved global economy.

2. Broadcom Limited ( (NASDAQ:AVGO) )

Semiconductor giant Broadcom is slated to release its latest quarterly report after the closing bell on December 6. After its bid for Qualcomm (NASDAQ:QCOM) was rejected, Broadcom will look to prove to investors—and potential takeover targets—that its financial position is strong. Shares of AVGO are already up over 55% this year.

As we approach its report date, Broadcom is sporting a Zacks Rank #2 (Buy). Paired with its Earnings ESP of 0.63%, this strong Zacks Rank makes us feel more comfortable about its chances to exceed expectations this quarter. Broadcom has met or surpassed estimates in 13 straight quarters.

Based on our latest consensus estimates, we expect Broadcom to report earnings of $4.50 per share and revenues of $4.82 billion. These results would represent year-over-year growth rates of +29.57% and +16.64%, respectively.

3. Lululemon Athletica Inc. ( (NASDAQ:LULU) )

Lululemon is scheduled to report its latest financial results after the market closes on December 6. This yoga-inspired athletic apparel retailer is still growing, especially in terms of brand recognition and popularity, but its stock has failed to generate much momentum. Shares of LULU have gained just 3% so far this year.

Heading into its upcoming earnings announcement, Lululemon is sporting a Zacks Rank #3 (Hold). According to our latest consensus estimates, the company is expected to post earnings of $0.52 per share and revenues of $611.47 million. These results would mark year-over-year growth rates of +10.77% and 12.32%, respectively.

Lululemon has surpassed earnings estimates in two consecutive quarters, and with an Earnings ESP of 0.12%, our model shows that investors could be in store for another beat next week.

Want more stock market analysis from this author? Make sure to follow @Ryan_McQueeney on Twitter!

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>